

Neuroallianz Press Release

26 November 2014

Neuroallianz Publication Award 2014

Three outstanding scientific papers in the area of neurodegenerative diseases awarded

For the first time the Strategic Advisory Board of the Neuroallianz Consortium granted the „Neuroallianz Publication Award“ for excellent scientific work in the area of neurodegenerative diseases to young scientists. The awardees are members of the Neuroallianz Consortium, a strategic partnership of academic and industry partners, focusing on research and development of innovative diagnostics and therapies. The objective is to progress novel approaches for neurodegenerative diseases from basic research to clinical development and finally to the patient. The biopharma company UCB as main industry partner of the consortium is donating the awards. The selection of the submitted publications is taken by an international jury composed of scientists from university and industry, the Strategic Advisory Board of the Neuroallianz Consortium. On behalf of this advisory board Dr. Barbara Stegmann, Neuroallianz Consortium Manager and Vice President BioDev Strategic Projects, Biopharma Development Solutions at UCB, as well as Dr. Bernward Garthoff, BIO.NRW, member of the Strategic Advisory Board of the Neuroallianz Consortium handed over the awards at the UCB site in Monheim, Germany.

This year the Gold award in the amount of 1.000 EUR went to a double publication on

- Structure of the human P2Y₁₂ receptor in complex with an antithrombotic drug and Agonist-bound structure of the human P2Y₁₂ receptor

The Silver award in the amount of 500 EUR went to the following publication:


- Different MicroRNA Profiles in Chronic Epilepsy Versus Acute Seizure Mouse Models

Silver (500 EUR) also went to the paper:

- 8-Benzyltetrahydropyrazino[2,1-f]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases

For the winner Dr. Andreas Brunschweiger from the Technical University of Dortmund the cooperation with various partners is a great support: „The many and valuable experiences I made within the scope of Neuroallianz I pass to my students. For me as scientist it was an important learning that it is not sufficient to synthesize bioactive substances. In fact there are multiple complex processes of drug optimization necessary before the drug can be applied to living organisms.

Dr. Barbara Stegmann: „It is exciting to observe how the cooperation between members of academic and industry partners becomes more intensive and understood and how learning from each other is increasing. This all inures to the benefit of the projects and thereby ultimately to the benefit of the patients“.



For Dr. Bernward Garthoff the Neuroallianz Publication Awards not only honors outstanding scientific papers but are also incentives for young scientists. „Without excellent science and the cooperation with industry in the network there will be no medical progress“.



The winners of the Neuroallianz Publication Award 2014
donated by the biopharma company UCB.

About the Neuroallianz-Konsortium:

The Neuroallianz Consortium, a public-private biopharma research alliance since 2009, focuses on the research and development of innovative diagnostics and therapeutics for improved treatment of neurodegenerative diseases. The consortium comprises of a strategic partnership between publicly funded research institutions, biotechnology companies and the pharmaceutical industry. Its objective is the translation of innovative research into novel therapeutic targets and diagnostics methods for improved staging of neurodegenerative diseases.

Academic partners of the Neuroallianz Consortium are: Rheinische Friedrich-Wilhelms-Universität Bonn, Universitätsklinikum Bonn, LVR-Klinikum Essen/Universitätsklinikum Essen, Forschungszentrum Jülich GmbH, Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e. V, Universitätsklinik Tübingen, Universität Göttingen, Helmholtz Zentrum Dresden-Rossendorf e.V. und Universität Tübingen. Industry partners are UCB Pharma GmbH, IBL International GmbH, Life&Brain GmbH, Cube Biotech GmbH, Pharmacelsus GmbH, Piramal Imaging GmbH, ROTOP Pharmaka GmbH, TEVA-ratiopharm, Immunogenetics AG, jung diagnostics GmbH.

About (add information on your institution/company here):

...

Contact:

*Dr. Barbara Stegmann, Neuroallianz Consortium Manager
Vice President BioDev Strategic Projects, Biopharma Development Solutions,
UCB BIOSCIENCES GmbH; Tel: +49-2173-48-1231; Barbara.Stegmann@ucb.com*

Note to Editors:**Gold Award:**

Structure of the human P2Y₁₂ receptor in complex with an antithrombotic drug
Journal Nature 2014, 509, 115-118

Kaihua Zhang^{1*}, Jin Zhang^{1*}, Zhan-Guo Gao², Dandan Zhang¹, Lan Zhu¹, GyeWon Han³, Steven M. Moss², Silvia Paoletta², Evgeny Kiselev², Weizhen Lu¹, Gustavo Fenalti³, Wenru Zhang¹, Christa E. Müller⁴, Huaiyu Yang⁵, Hualiang Jiang⁵, Vadim Cherezov³, Vsevolod Katritch³, Kenneth A. Jacobson², Raymond C. Stevens^{3,6}, Beili Wu¹ & Qiang Zhao¹

¹CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China

²Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA

³Department of Integrative Structural and Computational Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA

⁴PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, An der Immenburg 4, D-53121 Bonn, Germany

⁵Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China

⁶Human Institute, ShanghaiTech University, 99 Haik Road, Pudong, Shanghai 201203, China.

*These authors contributed equally to this work.

E-mail: christa.mueller@uni-bonn.de

Agonist-bound structure of the human P2Y₁₂ receptor

Journal Nature 2014, 509, 119-122

Jin Zhang^{1*}, Kaihua Zhang^{1*}, Zhan-Guo Gao², Silvia Paoletta², Dandan Zhang¹, GyeWon Han³, Tingting Li¹, Limin Ma¹, Wenru Zhang¹, Christa E. Müller⁴, Huaiyu Yang⁵, Hualiang Jiang⁵, Vadim Cherezov³, Vsevolod Katritch³, Kenneth A. Jacobson², Raymond C. Stevens^{3,6}, Beili Wu¹ & Qiang Zhao¹

¹CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China

²Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA

³Department of Integrative Structural and Computational Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA

⁴PharmaCenter Bonn, University of Bonn, Pharmaceutical Chemistry I, An der Immenburg 4, D-53121 Bonn, Germany

⁵Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China

⁶Human Institute, ShanghaiTech University, 99 Haik Road, Pudong, Shanghai 201203, China.

*These authors contributed equally to this work.

E-mail: christa.mueller@uni-bonn.de

Silver Award:

Different MicroRNA Profiles in Chronic Epilepsy Versus Acute Seizure Mouse Models

Journal J Mol Neurosci, DOI 10.1007/s12031-014-0368-6, Online veröffentlicht am 31. Juli 2014

Anita Kretschmann^{1*}, Benedicte Danis^{2*}, Lidija Andonovic¹, Khalid Abnaof³, Marijke van Rikxoort¹, Franziska Siegel¹, Manuela Mazzuferi², Patrice Godard⁴, Etienne Hanon², Holger Froehlich³, Rafal M. Kaminski², Patrik Foerch², Alexander Pfeifer^{1,5}

*These authors contributed equally to this work.

¹Institute of Pharmacology and Toxicology, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany

²UCB Pharma, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium

³Bonn-Aachen International Center for Information Technology (B-IT), Algorithmic Bioinformatics, University of Bonn, Dahlmannstr. 2, 53113 Bonn, Germany

⁴IP & Science, Thomson Reuters, 5901 Priestly Dr., #200, Carlsbad, CA 92008, USA

⁵PharmaCenter, University of Bonn, 53127 Bonn, Germany

E-mail: anita.kretschmann@uni-bonn.de

Silver Award:

8-Benzyltetrahydropyrazino[2,1-f]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases
Journal ChemMedChem 2014, 9, 1704-724

Andreas Brunschweiler, [a] Pierre Koch, [a] Miriam Schlenk, [a] Felipe Pineda, [b] Petra Kueppers, [a] Sonja Hinz, [a] Meryem Koese, [a] Stefan Ullrich, [a] Joerg Hockemeyer, [a] Michael Wiese, [b] Jag Heer, [c] and Christa E. Mueller* [a]

[a] Pharmaceutical Chemistry I, Pharmaceutical Institute, PharmaCenter Bonn, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany

[b] Pharmaceutical Chemistry II, Pharmaceutical Institute, PharmaCenter Bonn, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany

[c] CNS Research, Medicinal Chemistry & Lead Generation, UCB S.A., Chemin du Foriest, 1420 Braine l'Alleud, Belgium

[+] Current address: Faculty for Chemistry and Chemical Biology, TU Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany

[++] Current address: Institute of Pharmaceutical Sciences, Faculty of Science, Eberhard Karls Universität Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany

E-mail: andreas.brunschweiler@tu-dortmund.de